Want to see HIND full AI Analyst Report?
HIND Stock Chart & Stats
$2.23
$0.00(0.00%)
At close: 4:00 PM EDT
$2.23
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.75 - $6.56
Previous CloseN/A
Volume1.31K
Average Volume (3M)16.63K
Market Cap
$14.25M
Enterprise Value$8.48M
Total Cash (Recent Filing)$7.89M
Total Debt (Recent Filing)$17.31K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 24, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.90
Shares Outstanding7,018,528
10 Day Avg. Volume10,253
30 Day Avg. Volume16,632
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue65.39
Enterprise Value/Gross Profit140.63
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$9.25Price Target Upside314.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$59.50K
Bulls Say, Bears Say
Bulls Say
Low Balance-sheet LeverageLow leverage provides some financial flexibility and limits near-term interest and repayment pressure. This cushion could help the company preserve resources while pursuing operations or restructuring, although its benefit is constrained because persistent losses and cash burn may still require outside financing.
Positive Gross MarginA positive gross margin indicates the company retains some economics after direct costs, creating a base from which operating performance could improve if revenue stabilizes. However, the margin currently does not offset very large operating expenses and therefore has not yet translated into sustainable profitability.
Experienced Consulting CFO AppointmentAdding an experienced finance executive may strengthen reporting, controls and financial leadership during a period of severe operating weakness. The consulting structure also preserves cost flexibility, though the appointment is supportive rather than a direct solution to the company’s losses or funding needs.
Bears Say
Severe Revenue ContractionA roughly 90% revenue decline signals a major deterioration in commercial scale and weakens the operating base needed to support research, administration and growth investment. Unless revenue recovers materially, fixed costs will remain difficult to absorb and the path toward sustainable earnings will stay uncertain.
Persistent Deep UnprofitabilityDeep and persistent losses show that the company has not demonstrated a durable earnings model despite previously higher revenue levels. Continued negative profitability can consume financial resources, limit self-funded investment and increase the likelihood that shareholders face funding or dilution pressure over time.
Ongoing Cash Burn And Funding DependenceNegative operating and free cash flow across every reported period indicates that the business is not financing itself through operations. Even though the pace of free-cash-flow deterioration has moderated, continued burn may require external funding and can constrain strategic choices if current trends persist.
Vyome Holdings News
HIND FAQ
What was Vyome Holdings’s price range in the past 12 months?
Vyome Holdings lowest stock price was $1.75 and its highest was $6.56 in the past 12 months.
What is Vyome Holdings’s market cap?
Vyome Holdings’s market cap is $14.25M.
When is Vyome Holdings’s upcoming earnings report date?
Vyome Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 44 days.
How were Vyome Holdings’s earnings last quarter?
Vyome Holdings released its earnings results on Aug 25, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.09.
Is Vyome Holdings overvalued?
According to Wall Street analysts Vyome Holdings’s price is currently Undervalued.
Does Vyome Holdings pay dividends?
Vyome Holdings does not currently pay dividends.
What is Vyome Holdings’s EPS estimate?
Vyome Holdings’s EPS estimate is -0.2.
How many shares outstanding does Vyome Holdings have?
Vyome Holdings has 7,018,528 shares outstanding.
What happened to Vyome Holdings’s price movement after its last earnings report?
Vyome Holdings reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -0.535%.
Which hedge fund is a major shareholder of Vyome Holdings?
Currently, no hedge funds are holding shares in HIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
HIND Stock 12 Month Forecast
Average Price Target
$9.25
▲(314.80% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
Collplant Holdings
―
Dermata Therapeutics
―
Azitra Inc
―
Polyrizon Ltd.
―
Ownership Overview
6.48% Insiders
0.36% Mutual Funds
― Other Institutional Investors
92.95% Public Companies and
Individual Investors